TOBI Podhaler (tobramycin inhalation powder) — Medica
Cystic fibrosis with Pseudomonas aeruginosa in culture of the airway
Initial criteria
- Patient is age ≥ 6 years
- Patient has Pseudomonas aeruginosa in culture of the airway (e.g., sputum culture, oropharyngeal culture, or bronchoalveolar lavage culture)
- Medication is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis
Reauthorization criteria
- Patient was started on TOBI Podhaler and is continuing a course of therapy
Approval duration
initial: 1 year; continuation: 1 month